Study your flashcards anywhere!

Download the official Cram app for free >

  • Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key


Play button


Play button




Click to flip

9 Cards in this Set

  • Front
  • Back
Describe oxytocin
MOA: Oxytocin activates PLC-->increases synthesis of IP3-->triggers release of Ca2+ from SR-->activates MLCK, interaction b/t actin and myosin and uterine contraction
1. induce labor to facilitate delivery or inevitable abortion
2. control postpartum bleeding (uterine contraction compresses bleeding vessels)
3. treat breast engorgement during lactation
Side effects:
Large doses cause relaxation of vascular smooth muscle-->flushing and reflex tachycardia (obstetrical doses don't cause significant changes in BP)
describe dinoprostone
naturally occurring PGE2
1. abortifacient (Prostin E2)-to evacuate uterus after intrauterine death; vaginal suppositories contain highest dose of PGE2; intended for use during pregnancy weeks 12-20
2. induce cervical ripening (softening and dilation of cervix to allow expulsion of fetus)
a. Prepidil-endocervical gel containing lowest dose
b. Cervidil-vaginal insert containing medium dose
describe carboprost
15-methyl- of PGF2α (semisynthetic derivative of PGF2α)
1. abortifacient (given IM during wks 13-20)
2. to control postpartum bleeding
note-doesn't have direct effect on fetus (NOT feticidal); evacuate uterus via direct effects on uterine smooth muscle
describe mifepristone
progesterone receptor modulator
1. increases the sensitivity of the myometrium to contraction by PGs-->detachment of the conceptus from the uterine wall
2. cause vascular changes that decrease placental viability and decreases secretory activity of the myometrium-->cause sloughing of the endometrium
describe methylergonovine
class-oxytocic ergot alkaloid
MOA-stimulation of uterine smooth muscle at α1 (primary) and 5-HT receptors-->increase force and frequency of uterine contractions
1. postpartum or post-abortion to control bleeding
2. for postpartum atony of the uterus
Side effects:
1. IV-can lead to sudden hypertension and CVAs (give IV slowly)
2. headaches w/ HTN
describe magnesium sulfate
1. competes w/ Ca2+ to prevent contraction of uterine smooth muscle
2. antagonizes Ca2+ dependent neuronal depolarization
1. delay parturition
2. control seizures in pre-eclampsia or eclampsia
describe pre-eclampsia and eclampsia
PRE-ECLAMPSIA: characterized by HTN, edema and proteinuria
MOA-autoantibodies activate angiotensin II AT1 receptors Effect- can't increase levels of adrenomedullin during pregnancy; adrenomedullin is a vasodilator that stimulates production of nitric oxide, decreases aldosterone response to hyperkalemia and causes natriuresis
ECLAMPSIA-develops from severe HTN; characterized by convulsions and coma during pregnancy or 1st week postpartum
Severe HTN during pregnancy-treat w/ hydralazine or labetalol
describe terbutaline
β2 agonist
MOA-relaxes uterine smooth muscle
Use-controls pre-term labor (not approved)
FDA side effects:
1. parenteral terbutaline should not be used for prevention or prolonged treatment (> 48-72 hrs) of preterm labor due to risk of serious maternal cardiovascular events and death
2. oral use should not be used b/c it hasn't been shown effective and carries the same risks to mother as parenteral
describe Ca channel blockers
not approved as tocolytics (uterine contraction inhibitors)
Side effects:
1. pulmonary edema
2. dyspnea
3. MI
4. fetal death-due to drop in maternal BP decreasing fetal blood supply
1. Don't use w/ IV β agonists
2. Don't use IV nicardipine or high oral doses of nifedipine if mother is cardiovascularly compromised or if she's had multiple gestations
3. Monitor BP and cardiotocography when using immediate release formulations